Gyre Therapeutics to Present Promising Phase 3 Results for Liver Fibrosis Treatment at Major Medical Conference
Gyre Therapeutics Announces Phase 3 Results for Liver Fibrosis Treatment at The Liver Meeting® 2025
Gyre Therapeutics (Nasdaq: GYRE), a leading biopharmaceutical company known for its commitment to developing advanced therapies targeting fibrosis, revealed that it will present results from its successful Phase 3 clinical trial evaluating Hydronidone. Hydronidone is a novel anti-fibrotic agent designed to inhibit the activation of hepatic stellate cells (HSCs) and encourage their apoptosis, making it a promising candidate for treating liver fibrosis in patients with chronic hepatitis B.
The findings will be featured at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), held in Washington, D.C., from November 7 to 10, 2025. The study results have earned the distinction of being selected for the prestigious Poster of Distinction category.
Presentation Details
- Session Title: Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B
- Presenting Author: Prof. Lungen Lu, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Session: Hepatitis B
- Date/Time: Friday, November 7, 2025, 8:00 a.m. – 5:00 p.m. Eastern Time
- Publication Number: 1121
About Gyre Therapeutics
Based in San Diego, Gyre Therapeutics primarily focuses on developing and commercializing Hydronidone for treating liver fibrosis, including conditions like MASH (metabolic dysfunction-associated steatohepatitis), in the United States. The company leverages its expertise in preclinical and clinical research, using MASH rodent models and studies involving chronic hepatitis B-induced liver fibrosis. Internationally, particularly in China, Gyre Therapeutics is also developing additional treatments such as ETUARY®, F573, F528, and F230 through Gyre Pharmaceuticals, a company in which it holds an indirect controlling interest.
Continued corporation investment in innovative biopharmaceutical research underscores Gyre’s commitment to tackling complex chronic diseases.
This content is for informational purposes only and does not constitute financial advice.
